iOnctura
iOnctura is a clinical-stage biopharmaceutical company dedicated to developing high impact, low disruption therapies that extend healthspan by targeting neglected and hard-to-treat cancers. The company focuses on innovative treatments that disrupt the tumor-stroma-immune interface, aiming to improve patient outcomes with less toxic options. Their pipeline includes promising small molecules like roginolisib, cambritaxestat, and IOA-359, which target key pathways involved in cancer progression. Led by a team of experienced experts and supported by strategic investors, iOnctura is committed to pioneering bold new treatments and making a meaningful impact in oncology.
Industries
Nr. of Employees
small (1-50)
iOnctura
Campus Biotech, Avenue Sécheron 15, 1202 Genève, Switzerland
Patents
Products
Oral PI3Kδ-targeting allosteric small molecule (clinical-stage)
A selective, orally administered allosteric modulator of the PI3Kδ isoform developed to rebalance tumour immune microenvironments and inhibit PI3Kδ-driven tumor survival; being evaluated across uveal melanoma, NSCLC, myelofibrosis and hematological indications in Phase I/II studies.
Oral autotaxin inhibitor for fibrotic and metastatic tumours (clinical-stage)
Orally dosed small-molecule autotaxin inhibitor designed to inhibit catalytic and chaperone activities of autotaxin, reduce LPA signalling, reduce fibrosis and stimulate immune cell infiltration; under clinical evaluation in combination with chemotherapy for pancreatic cancer and other fibrotic tumours.
Oral TGF-β pathway small-molecule inhibitor (development-stage)
Small-molecule inhibitor targeting the TGF-β signalling pathway intended for use in solid tumours and in rational combination regimens to overcome pathway-mediated resistance.
Oral PI3Kδ-targeting allosteric small molecule (clinical-stage)
A selective, orally administered allosteric modulator of the PI3Kδ isoform developed to rebalance tumour immune microenvironments and inhibit PI3Kδ-driven tumor survival; being evaluated across uveal melanoma, NSCLC, myelofibrosis and hematological indications in Phase I/II studies.
Oral autotaxin inhibitor for fibrotic and metastatic tumours (clinical-stage)
Orally dosed small-molecule autotaxin inhibitor designed to inhibit catalytic and chaperone activities of autotaxin, reduce LPA signalling, reduce fibrosis and stimulate immune cell infiltration; under clinical evaluation in combination with chemotherapy for pancreatic cancer and other fibrotic tumours.
Oral TGF-β pathway small-molecule inhibitor (development-stage)
Small-molecule inhibitor targeting the TGF-β signalling pathway intended for use in solid tumours and in rational combination regimens to overcome pathway-mediated resistance.
Services
Design and conduct of Phase I and Phase II clinical trials, including dose-escalation, dose-confirmation and randomized studies in oncology.
Preclinical-to-clinical translational studies and development of molecular biomarkers including ctDNA profiling to support patient selection and mechanism evaluation.
In vivo and in vitro preclinical testing in tumour models to evaluate efficacy, immune infiltration, anti-fibrotic effects and mechanism of action prior to clinical entry.
Preparation and management of regulatory interactions and submissions including IND processes, orphan drug designation applications and coordination with health authorities.
Establishing and operationalising clinical collaborations with commercial partners for drug supply and combination studies.
Design and conduct of Phase I and Phase II clinical trials, including dose-escalation, dose-confirmation and randomized studies in oncology.
Preclinical-to-clinical translational studies and development of molecular biomarkers including ctDNA profiling to support patient selection and mechanism evaluation.
In vivo and in vitro preclinical testing in tumour models to evaluate efficacy, immune infiltration, anti-fibrotic effects and mechanism of action prior to clinical entry.
Preparation and management of regulatory interactions and submissions including IND processes, orphan drug designation applications and coordination with health authorities.
Establishing and operationalising clinical collaborations with commercial partners for drug supply and combination studies.
Expertise Areas
- Small-molecule drug discovery
- Medicinal chemistry
- Oncology clinical development (Phase I/II)
- Translational biomarker research and molecular profiling
Key Technologies
- Allosteric kinase modulation (PI3Kδ)
- Autotaxin inhibition
- TGF-β pathway inhibition
- Oral small-molecule therapeutics
News & Updates
Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, with patients showing doubled overall survival compared to historical controls.
Completed Phase I DIONE-01 study demonstrates clinical activity and long-term safety of roginolisib, with patients showing doubled overall survival compared to historical controls.